Clinical reference Biomarker Directory
Back to directory

Clostridium difficile glutamate dehydrogenase

Established

GDH is a sensitive but nonspecific screening step in multistep C. difficile testing algorithms.

Also known as GDH C. diff GDH antigen
In plain language

GDH is a quick screening test for a gut infection called C. difficile. A negative result is very reassuring that a patient doesn't have it, but a positive result needs a second, more specific test before doctors treat it as a true active infection.

Biomarker & context

Glutamate dehydrogenase (GDH) is a metabolic enzyme present in high levels in all Clostridioides difficile isolates, used as a rapid screening component in C. difficile infection (CDI) testing algorithms.

What it indicates

A positive GDH result indicates the presence of C. difficile organisms (toxigenic or non-toxigenic) in stool, but does not confirm active toxin-mediated infection, since GDH cannot distinguish disease-causing strains from harmless colonization.

Diagnosis & clinical testing

Current IDSA guidelines specifically recommend GDH not be used alone — it is highly sensitive but poorly specific, so it is paired with a toxin EIA and/or nucleic acid amplification test (NAAT) in a multistep testing algorithm.

Guiding treatment

A negative GDH has a very high negative predictive value (often >98%), meaning it is genuinely reassuring for ruling out C. difficile infection, while a positive GDH requires confirmatory toxin or NAAT testing before treatment decisions are made.

Clinical significance

Excellent negative predictive value; positive results require confirmatory toxin or molecular testing.

References
  1. IDSA. Clinical Practice Guidelines for Clostridium difficile Infection.
  2. PMC. (2012). Glutamate Dehydrogenase for Laboratory Diagnosis of Clostridium difficile Infection.